Article

Formulation and Evaluation of Levofloxacin Using Different Types and Concentrations of Superdisintegrants

Journal of Pharmaceutical Sciences and Research 01/2010;
Source: DOAJ

ABSTRACT Levofloxacin is a fluoroquinolone anti bacterial drug effective in the treatment of bacterial conjunctivitis. Levofloxacin is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class. The objective of the present work was to comparison of super disintegrants on Levofloxacin oral formulations. Levofloxacin oral formulations were prepared with different concentrations (5%, 10%), of each super disintegrants. The super integrants were sodium starch glycolate (SSG), crosspovidone (XL-10) and crosscarmellose sodium (CCS) usedin the preparation of Levofloxacin oral formulations. The formulations were coded as Lev1 (SSG), Lev2 (Cross povidone) and Lev3 (CCS). The Levofloxacin oral formulation (Lev2) with cross povidone (XL-10) 10% has shown the better disintegration time and increases the dissolution rate when compared to the other super disintegrants.

6 Bookmarks
 · 
571 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Campylobacter species cause 1.4 million infections each year in the United States. Fluoroquinolones (e.g., ciprofloxacin) are commonly used in adults with Campylobacter infection and other infections. Fluoroquinolones (e.g., enrofloxacin) are also used in veterinary medicine. Human infections with fluoroquinolone-resistant Campylobacter species have become increasingly common and are associated with consumption of poultry. These findings, along with other data, prompted the US Food and Drug Administration to propose the withdrawal of fluoroquinolone use in poultry in 2000. A lengthy legal hearing concluded with an order to withdraw enrofloxacin from use in poultry (effective in September 2005). Clinicians are likely to continue to encounter patients with fluoroquinolone-resistant Campylobacter infection and other enteric infection because of the continued circulation of fluoroquinolone-resistant Campylobacter species in poultry flocks and in persons returning from foreign travel who have acquired a fluoroquinolone-resistant enteric infection while abroad. Judicious use of fluoroquinolones and other antimicrobial agents in human and veterinary medicine is essential to preserve the efficacy of these important chemotherapeutic agents.
    Clinical Infectious Diseases 05/2007; 44(7):977-80. · 9.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of new drugs with strong antituberculous activity and fewer side effects which are not cross-resistant to conventional antituberculosis drugs is urgently desired now. The chemotherapeutic agents under study which are considered a candidate for a new antituberculosis drug are listed below. 1) Rifamycin derivatives: rifabutin, rifapentin, KRM-1648, FCE-22250, 22807, CGP-7040, 27557, 29035, 29861, P-DEA, SPA-S-565, R-76-1. 2) New quinolones: ofloxacin, ciprofloxacin, levofloxacin, sparfloxacin, gatifloxacin, CS-940, Du-6859a. 3) Phenazines: clofazimine, B746, B4101, B4154, B4157. 4) Pyrazinamide derivatives: N-hydroxy pyrazinamide, N-hydroxy pyrazinamide-4-oxide. 5) Nitroimidazole derivatives: metronidazole et al.
    Nippon rinsho. Japanese journal of clinical medicine 01/1999; 56(12):3096-9.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The etiology of urinary tract infections (UTIs) that require hospitalization, whether they originate in the hospital or in the community, is changing, with increasing findings of gram-positive organisms. The Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria recommend evaluating treatment choices on the basis of sound clinical evidence, potential for therapeutic benefits, safety, optimal duration of treatment, and cost-efficacy in order to improve antibiotic treatment. Evidence-based guidelines recommend fluoroquinolones for the treatment of patients with cases of pyelonephritis or bacterial prostatitis severe enough to warrant hospitalization. For other serious UTIs, fluoroquinolones are usually recommended either when traditional agents have failed or when resistance to traditional agents is high. Even in the context of rapidly changing antimicrobial resistance patterns, the fluoroquinolones have maintained consistent, well-tolerated efficacy against many of the principal organisms responsible for UTIs, and are generally considered safe for most patients. To increase the likelihood of treatment success with first-line therapy, an antimicrobial agent must attain sufficient concentrations in the target tissue or in the urine for an appropriate amount of time. Both levofloxacin and gatifloxacin are excreted unchanged in the urine in concentrations that far exceed the minimum inhibitory concentration of most uropathogens. Factors that affect cost-effectiveness that should be considered include acquisition costs as well as treatment success and ease of use for hospital staff.
    The American Journal of Medicine 08/2005; 118 Suppl 7A:14S-20S. · 5.30 Impact Factor

Full-text (2 Sources)

Download
94 Downloads
Available from
Jun 1, 2014